Skip to main content
OpenTrials
Completed

NCT Number: NCT01545310

A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia

This open-label, Phase 1 study will investigate the 5-hydroxytryptamine 6 (5-HT6) receptor occupancy in the brain using positron emission tomography (PET) following single oral doses of SLV354. Up to 22 healthy male subjects and male subjects with stable schizophrenia, between 18-55 years of age are to complete the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Site Reference ID/Investigator# 52162

New Haven, Connecticut, 06520-8048, United States

About this study

This is an exploratory, open-label PET study designed to examine the relationship between SLV354 plasma concentration and 5-HT6 receptor occupancy in the brain following single oral doses of SLV354 in healthy male subjects and male subjects with stable schizophrenia. A total of up to 22 subjects are to complete the study, including approximately 12 subjects with schizophrenia on a stable dose of an atypical antipsychotic medication. Within 60 days prior to the PET scan, subjects will be screened based on medical history, physical examination, vital signs, ECG, clinical laboratory tests, response to Columbia-Suicide-Severity Rating Scale (C-SSRS) and for schizophrenia subjects only, the diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR). Following Screening, eligible subjects will have a Magnetic Resonance Imaging (MRI) scan, unless one was performed within one year of the PET scan, to delineate the region of interest for the individual PET images. The radiotracer [11C]-QUICS will be used for the PET scans.

All subjects will receive a single oral dose of SLV354. Healthy subjects will have one PET scan prior to and two PET scans after administration of SLV354. Schizophrenia subjects will have two PET scans prior to and one PET scan after administration of SLV354.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male, age between 18 and 55 years, inclusive.
  • Body Mass Index 18 to 30 (healthy) and 18 to 38 (schizophrenia).
  • A condition of general good physical health.
  • Schizophrenia subjects must have a diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR).
  • Schizophrenia subjects must be on a stable dose of an atypical antipsychotic for at least 4 weeks prior to Screening.

Exclusion criteria

  • Presence of a metal implant that would preclude a Magnetic Resonance Imaging (MRI) scan.
  • Radiation exposure for research purposes within the past year that will exclude participation in the study.
  • Significant current suicidal ideation within the past month as evidenced by Columbia-Suicide Severity Rating Scale (C-SSRS) completed at Screening.
  • History of psychiatric diseases or disorders (healthy subjects)
  • Unsuitable to receive SLV354 or the radiotracer, [11C]-QUICS.

Treatment and study plan

SLV354

Drug

One dose of ABT-354

Other names: ABT-354

Primary outcomes

  1. Brain receptor occupancy

    Time frame: Study Day -1

    5-HT6 receptor occupancy and the relationship between SLV354 plasma concentrations and receptor occupancy

  2. Brain receptor occupancy

    Time frame: Study Day 1

    5-HT6 receptor occupancy and the relationship between SLV354 plasma concentrations and receptor occupancy

Secondary outcomes

  1. Pharmacokinetic profile

    Time frame: Up through Study Day 4

    Maximum observed plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration-time curve (AUC), terminal elimination half-life (t1/2), oral plasma clearance (CL/F)

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

An Open-Label, Positron Emission Tomography (PET) Study to Evaluate the Brain 5 HT6 Receptor Occupancy by Single Doses of SLV354 in Healthy Male Subjects and Subjects With Stable Schizophrenia

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Mar 6, 2012
Registry last updated
Sep 18, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.